Last reviewed · How we verify
H-1PV
At a glance
| Generic name | H-1PV |
|---|---|
| Also known as | ParvOryx (brand name of H-1PV) |
| Sponsor | Oryx GmbH & Co. KG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer (PHASE1, PHASE2)
- Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H-1PV CI brief — competitive landscape report
- H-1PV updates RSS · CI watch RSS
- Oryx GmbH & Co. KG portfolio CI